Neurotrope To Release Results From Phase II Clinical Trial In Moderate To Severe Alzheimer’s Disease On May 1, 2017
NEW YORK, April 28, 2017 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, will issue a press release announcing results of top-line data from its 148 patient, Phase 2 clinical trial in moderate to severe Alzheimer's Disease, on Monday May 1, 2017, at 6:30 am, Eastern Time. A conference call will follow at 8:30 am Eastern Time on that date.
The dial-in information to access the live call is listed below:
Participant Toll Free Dial-In Number:
(877) 245-7303
Participant International Dial-In Number:
(478) 219-0731
Conference ID:
16070779
The dial-in information to access the call replay, available for 30 days after the live call, is listed below:
Replay Toll Free Dial-In Number:
(800) 585-8367
Replay International Dial-In Number:
(404) 537-3406
Conference ID:
16070779
Callers should dial in approximately 10 minutes before the live call begins.
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's dementia and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein Kinase C isozymes e and a by Bryostatin-1, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's dementia.
Neurotrope has conducted a Phase 2 trial of Bryostatin-1 in the treatment of moderate to severe Alzheimer's dementia, as well as preclinical studies of Bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.
The dial-in information to access the live call is listed below:
Participant Toll Free Dial-In Number:
(877) 245-7303
Participant International Dial-In Number:
(478) 219-0731
Conference ID:
16070779
The dial-in information to access the call replay, available for 30 days after the live call, is listed below:
Replay Toll Free Dial-In Number:
(800) 585-8367
Replay International Dial-In Number:
(404) 537-3406
Conference ID:
16070779
Callers should dial in approximately 10 minutes before the live call begins.
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's dementia and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein Kinase C isozymes e and a by Bryostatin-1, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's dementia.
Neurotrope has conducted a Phase 2 trial of Bryostatin-1 in the treatment of moderate to severe Alzheimer's dementia, as well as preclinical studies of Bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.